Longevica Therapeutics Formed Scientific Advisory Board
The San Francisco biotech firm has pivoted to clinical execution after a four-year mammalian screening program.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you trust private biotech companies to successfully develop credible treatments to extend human lifespan?
Longevica Therapeutics announced the formation of a Scientific Advisory Board, signaling a transition from foundational discovery to clinical development. The San Francisco-based company focuses on developing therapeutics for age-related diseases.
Why it matters
This move marks the company’s pivot toward translating early-stage lifespan research into human clinical applications. It follows a completed four-year screening program that sought compounds capable of extending mammalian lifespans.
The company’s $13 million screening program evaluated 1,033 small-molecule compounds across 16,000 subjects to identify lifespan-extending properties. This data informed the development of two proprietary therapeutic classes.
The players
Longevica Therapeutics
A biotechnology company headquartered in San Francisco and New York that develops small-molecule therapeutics based on full-lifespan mammalian screening data.
Dr. Prasun Mishra
The current Chief Executive Officer of Longevica Therapeutics who is leading the company's transition from research to clinical-stage drug development.
The Jackson Laboratory
An independent, nonprofit biomedical research institution that served as the site for Longevica's multi-year mammalian screening program.
The details
Longevica uses predictive machine learning algorithms trained on prospective full-lifespan mammalian outcomes to identify candidate drugs. The company tracks these compounds across the entire natural lifespans of 16,000 subjects at The Jackson Laboratory, an independent biomedical research institution. These efforts aim to isolate compounds that consistently influence longevity metrics in mammals, which the company is now refining for clinical development.
Timeline
September 29, 2026: Longevica announced the formation of its scientific advisory board.
The Tech Race
Longevica’s approach mirrors the systematic methodology used by the National Institute on Aging Interventions Testing Program but moves it into a private, commercialized pipeline. The company is now competing to be among the first to translate successful mammalian screening results into clinically viable age-related disease therapeutics.
The company’s current focus is restricted to preclinical research, meaning these findings do not yet impact existing medical treatments or consumer healthcare. Patients and clinicians should await future disclosures regarding clinical trial timelines and therapeutic indications.
The takeaway
Longevica is shifting its operational model from high-throughput mammalian screening to the commercial development of longevity-extending compounds. Interested parties should monitor the firm’s upcoming disclosures regarding clinical trial progress and the biological targets of its two new therapeutic classes.
Further reading
For more on the current landscape of longevity research, visit Biotech.
More information
View the Longevica company pipeline and research for additional details on their proprietary drug development programs.
Live Poll
Do you trust private biotech companies to successfully develop credible treatments to extend human lifespan?
